Paul Hastings Adds Leading Equity Capital Markets and Life Sciences Partner

NEW YORK  – Paul Hastings LLP announced today that experienced capital markets lawyer Seo Salimi has joined the firm in New York as a partner, co-head of the equity capital markets practice, and co-chair of corporate life sciences practice.

Joining from Goodwin Procter LLP, Salimi’s practice is focused on representing life sciences companies and underwriters in a wide variety of transactions, including initial public offerings, followon offerings, private placements, cross-border offerings and “at-the-market” offerings. He also advises public and private companies in their capital-raising strategies, as well as SEC compliance and corporate governance matters.

“With his concentration in equity capital markets and life sciences—advising innovative companies, as well as leading underwriters and investors—Seo is a key addition to our capital markets practice and further elevates our overall platform in global finance,” said firm Chair Frank Lopez. “Seo will further strengthen and position us for IPOs and other complex equity capital markets matters in the life sciences sector, and more broadly, as we continue to enhance our platform to represent clients on a broad range of their most important and complex matters.”

Salimi has served as a trusted adviser to dozens of leading-edge life science companies developing gene therapies, CNS drugs, CRISPR-based therapies, T-cell therapies, AI-based drug discovery, and other advanced areas of bioscience. He also represents leading banks and financial services firms, including Goldman Sachs & Co., J.P. Morgan Securities LLC, SVB Securities LLC, Jefferies LLC, Citigroup Global Markets Inc., and Cantor Fitzgerald & Co.

Salimi’s high-profile IPOs and other equity capital markets deals include representing Karuna Therapeutics, Inc., in its IPO and follow-on offerings with an aggregate value exceeding $1.5 billion in proceeds; CRISPR Therapeutics AG in its IPO and follow-on offerings with an aggregate value exceeding $1 billion in proceeds; Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC as underwriters in Sarepta’s Therapeutics, Inc. equity offerings with an aggregate value exceeding $1.5 billion in proceeds; and Goldman Sachs & Co. LLC, Morgan Stanley & Co., and BofA Securities LLC as underwriters in Exscientia plc’s $500 million IPO.

“Paul Hastings has one of the legal industry’s best and most diverse capital markets brands. The depth of experience and industry relationships uniquely positions the firm to advise life science companies through every stage of their life cycle and execute equity transactions with the highest level of skill and quality for its clients,” said Salimi, who has been recognized as a “Next Generation Partner” by The Legal 500 United States, recognized by IFLR1000, and nominated by LMG Life Sciences for the “U.S. Rising Star – Financial & Corporate” award. “I’m excited to work with the incredibly talented team here and to expand Paul Hastings’ reputation as a preeminent firm for life sciences and equity capital markets.”

Paul Hastings’ capital markets practice helps clients, from public companies and investment banks to private equity and venture capital firms, navigate every stage of the capital raising process by advising issuers, underwriters, sponsors, and other financial institutions on strategies for all types of equity and debt capital raisings. Among its many recognitions, the practice was named Law360’s “Capital Markets Practice Group of the Year” and has earned recognition for its high-yield expertise by Chambers USA.

About Paul Hastings

With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment, and real estate, Paul Hastings is a premier law firm providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers, and corporations.